The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy, and to the agents, commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
HarousseauJ.L., AttalM., LeleuX.. Bortezomib plus dexamethasone as induction treatment prior to autologus stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica.2006; 91(11): 1498–1505.
2.
JagannathS., DurieB., WolfJ.. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol.2005; 129(6): 776–783.
3.
JagannathS., DurieB., WolfJ.. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol.2009; 146(6): 619–626.
4.
HarousseauJ., AttalM., LeleuX.. Bortezomib (Velcade) plus dexamethasone as induction treatment prior to autologus stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. J Clin Oncol.2005 (abstract 6653). http://www.asco.org. Accessed September 2, 2009.
5.
HarousseauJ., MaritG., CaillotD.. Velcade/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologus stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial. Blood.2006 (abstract 56). http://abstracts.hematologylibrary.org. Accessed October 9, 2009.
6.
JagannathS., DurieB., WolfJ.. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood.2006 (abstract 796). http://abstracts.hematologylibrary.org. Accessed October 9, 2009.
7.
MikhaelJ., BelchA., PrinceH.High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol.2008; 144(2): 169–175.
8.
JagannathS., BarlogieB., BerensonJ.. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol.2004; 127(2): 165–172.
9.
JagannathS., RichardsonP., BarlogieB.. Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone. Proc Am Soc Clin Oncol.2003 (abstract 2341). http://www.asco.org. Accessed September 2, 2009.
10.
OzakiS., TanakaO., FujiiS.. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma [abstract]. Int J Hematol.2007; 86(2): 180–185.
11.
RosinolL., OriolA., MateosM.V.. Phase II Pethema trial of alternating bortezomib and Dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Onc.2007; 25(28): 4452–4458.
12.
SuvannasankhaA., SmithG.G., JuliarB.E., AbonourR.Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma [abstract]. Clin Lymphoma Myeloma.2006; 7(2): 131–134.
13.
YuanZ.G., HouJ., ZhouF.. Bortezomib in combination with Dexamethasone for the treatment of relapsed or refractory multiple myeloma [abstract]. Zhonghua Xue Ye Xue Za Zhi.2006; 27(10): 653–655.
14.
National Cancer Comprehensive Network.NCCN Clinical Practice Guidelines – Multiple Myeloma. V.2.2010. http://www.nccn.org. Accessed October 13, 2009.
15.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. V.4.2009 http://www.nccn.org. Accessed October 4, 2009.
16.
KrisM.G., HeskethP.J., SomerfieldM.R..; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
17.
Multinational Association for Supportive Care in Cancer.Antiemetic Guidelines. 2008. http://www.mascc.org. Accessed October 9, 2009.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. v.1.2009. http://www.nccn.org. Accessed October 9, 2009.
20.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol.2006; 24(19): 3187–3205.
21.
BoyiadzisM.M., LebowitzP.F., FrameJ.N., FojoT.Hematology-Oncology Therapy.New York, NY: McGraw-Hill; 2007: 570–578.
22.
AronoffG.R., BennettW.M., BernsJ.S., BrierM.E., KasbekarN., MuellerB.A., PaskoD.A., SmoyerWE. Drug Prescribing in Renal Failure.5th ed.Philadelphia, PA: American College of Physicians; 2007.
23.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of Chemotherapy. Semin Oncol.2006; 33(1): 50–67.
24.
KingP.D.Perry MC. Hepatotoxicity of Chemotherapy. Oncologist.2001; 6(2): 162–176.
